BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news
Investing.comMonday, September 15, 2025 at 7:53:54 AM
NegativeFinancial Markets

BMO Capital has downgraded the stock rating of Tourmaline Bio following news of Novartis's acquisition. This decision reflects concerns about the impact of the acquisition on Tourmaline's market position.
Editor’s Note: This downgrade is significant as it may influence investor confidence in Tourmaline Bio. Acquisitions can reshape market dynamics, and BMO's action suggests they foresee challenges ahead for the company.
— Curated by the World Pulse Now AI Editorial System